RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Clinical trials for RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for japanese AML patients: experimental drug ziftomenib enters trial
Disease control Recruiting nowThis study tests an experimental drug called ziftomenib in 6 Japanese adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drug is taken as a pill once daily. The goal is to see if it can help control the disease and how…
Matched conditions: RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack…
Matched conditions: RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC